Sanofi-aventis’ new insulin injection more efficient (Trade Arabia)
Sanofi-aventis has announced the results of new analysis that found a significantly lower risk of nocturnal hypoglycemia with Lantus (insulin glargine [rDNA] injection) as compared to NPH insulin.
Merz Pharmaceuticals Announces Phase III Data for NT 201 in Post-stroke Upper Limb Spasticity (EarthTimes)
Data results published this month in Clinical Neuropharmacology, revealed that Merz Pharmaceuticals’ NT 201 (botulinum toxin type A free from complexing proteins), also known by the brand name Xeomin in Europe and Canada, was statistically significantly more efficacious than placebo for the treatment of patients with post-stroke upper limb spasticity. The Phase III study assessed the impact of NT 201 on muscle tone, functional disability and caregiver burden in patients with post-stroke upper limb spasticity, utilizing a randomized, placebo-controlled, double-blind design.
EU antitrust regulators raid drugmakers (Reuters)
EU antitrust regulators raided several pharmaceutical companies suspected of violating EU antitrust rules on Tuesday as they stepped up their crackdown on drugmakers seen as delaying the launch of cheaper medicines.
Sanofi’s Multaq Unlikely to Be a Blockbuster, Says Analyst (bnet.com)
Before Sanofi-Aventis launched its heart drug Multaq, some analysts estimated revenues would top €3 billion. But 10 weeks into the launch, Multaq looks like a much more modest affair, according to a note to investors from Jefferies International.
SUBSCRIBE